Back to Search
Start Over
Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs
- Source :
- Bornebusch, A B, Fink-Jensen, A, Wörtwein, G, Seeley, R J & Thomsen, M 2019, ' Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs ', eNeuro, vol. 6, no. 2, e0443-18.2019 . https://doi.org/10.1523/ENEURO.0443-18.2019
- Publication Year :
- 2019
-
Abstract
- Dependence on opioids and the number of opioid overdose deaths are serious and escalating public health problems, but medication-assisted treatments for opioid addiction remain inadequate for many patients. Glucagon-like pepide-1 (GLP-1) is a gut hormone and neuropeptide with actions in peripheral tissues and in the brain, including regulation of blood glucose and food intake. GLP-1 analogs, which are approved diabetes medications, can reduce the reinforcing and rewarding effects of alcohol, cocaine, amphetamine, and nicotine in rodents. Investigations on effects of GLP-1 analogs on opioid reward and reinforcement have not been reported. We assessed the effects of the GLP-1 receptor agonist Exendin-4 (Ex4) on opioid-related behaviors in male mice, i.e., morphine-conditioned place preference (CPP), intravenous self-administration (IVSA) of the short-acting synthetic opioid remifentanil, naltrexone-precipitated morphine withdrawal, morphine analgesia (male and female mice), and locomotor activity. Ex4 treatment had no effect on morphine-induced CPP, withdrawal, or hyperlocomotion. Ex4 failed to decrease remifentanil self-administration, if anything reinforcing effects of remifentanil appeared increased in Ex4-treated mice relative to saline. Ex4 did not significantly affect analgesia. In contrast, Ex4 dose dependently decreased oral alcohol self-administration, and suppressed spontaneous locomotor activity. Taken together, Ex4 did not attenuate the addiction-related behavioral effects of opioids, indicating that GLP-1 analogs would not be useful medications in the treatment of opioid addiction. This difference between opioids and other drug classes investigated to date may shed light on the mechanism of action of GLP-1 receptor treatment in the addictive effects of alcohol, central stimulants, and nicotine.
- Subjects :
- Male
Agonist
medicine.drug_class
media_common.quotation_subject
Remifentanil
Motor Activity
Pharmacology
Glucagon-Like Peptide-1 Receptor
Nicotine
Mice
medicine
Animals
Hypoglycemic Agents
Amphetamine
Glucagon-like peptide 1 receptor
media_common
Mice, Knockout
Behavior, Animal
business.industry
gut-brain axis
substance use disorder
General Neuroscience
Addiction
neuropeptides
operant behavior
Opioid overdose
General Medicine
Opioid-Related Disorders
medicine.disease
abuse
Mice, Inbred C57BL
Alcoholism
Opioid
opioid
Conditioning, Operant
Exenatide
business
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Bornebusch, A B, Fink-Jensen, A, Wörtwein, G, Seeley, R J & Thomsen, M 2019, ' Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs ', eNeuro, vol. 6, no. 2, e0443-18.2019 . https://doi.org/10.1523/ENEURO.0443-18.2019
- Accession number :
- edsair.doi.dedup.....931c24c70ae0138e8e08afb3bcd82921
- Full Text :
- https://doi.org/10.1523/ENEURO.0443-18.2019